Main Article Content
A strong controversy has emerged about the reality of safety and efficacy of statins as stated by company-sponsored reports. However, physicians need credible data to make medical decisions, in particular about the benefit/harm balance of any prescription. This study aimed to test the validity of data on the company-sponsored statin trial by comparing them over time and then comparing statins with each other. Around the years 2005/2006, new stricter Regulations were introduced in the conduct and publication of randomized controlled trials (RCTs). This would imply that RCTs were less reliable before 2006 than they were later on. To evaluate this, we first reviewed RCTs testing the efficacy of statins versus placebo in preventing cardiovascular complications and published after 2006. Our systematic review thereby identified four major RCTs, all testingrosuvastatin. They unambiguously showed that rosuvastatin is not effective in secondary prevention, while the results are highly debatable in primary prevention. Because of the striking clinical heterogeneity and the inconsistency of the published data in certain RCTs, meta-analysis was not feasible. We then examined the most recent RCTs comparing statins to each other: all showed that no statin is more effective than any other, including rosuvastatin. Furthermore, recent RCTs clearly indicate that intense cholesterol-lowering (including those with statins) does not protect high-risk patients any better than less-intense statin regimens. As for specific patient subgroups, statins appear ineffective in chronic heart failure and chronic kidney failure patients. We also conducted a MEDLINE search to identify all the RCTs testing a statin against a placebo in diabetic patients, and we found that once secondary analyses and subgroup analyses are excluded, statins do not appear to protect diabetics. As for the safety of statin treatment – a major issue for medical doctors – it is quite worrisome to realize that it took 30 years to bring to light the triggering effect of statins on new-onset diabetes, manifestly reflecting a high level of bias in reporting harmful outcomes in commercial trials, as has been admitted by the recent confession of prominent experts in statin treatment. In conclusion, this review strongly suggests that statins are not effective for cardiovascular prevention. The studies published before 2005/2006 were probably flawed, and this concerned in particular the safety issue. A complete reassessment is mandatory. Until then, physicians should be aware that the present claims about the efficacy and safety of statins are not evidence based.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
2. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ. 2014;348:g2263.
3. Loder E, Tovey D, Godlee F. The Tamiflu trials. BMJ. 2014;348:g2630.
4. Seife C. Is drug research trustworthy? The pharmaceutical industry funnels money to prominent scientists who are doing research that affects its products—and nobody can stop it. Sci Am. 2012;307:56-63.
5. Statins expert calls for safety checks over the drug. http://www.express.co.uk/news/uk/558249/statins-expert-heart-drug-rory-collins
6. Collins R. “Not for publication” Letter addressed to the BMJ Editors. http://journals.bmj.com/site/bmj/statins/SP17%20Letter%201%20from%20Rory%20Collins%20to%20FG%20dated%2031%20March%20Not%20for%20Publication.pdf
7. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.
8. Sever P. The BMJ statins papers misrepresent the facts. BMJ. 2014;348:g4030.
9. Godlee F. Adverse effects of statins. BMJ. 2014;348:g3306.
10. Fahey T, Smith S. Retraction of statins article is not in the public interest: better characterisation of benefits and risks is crucial. BMJ. 2014;348:g4028.
11. Goldacre B, Godlee F, Heneghan C, Tovey D, Lehman R, Chalmers I, et al. Open letter: European Medicines Agency should remove barriers to access clinical trial data. BMJ. 2014;348:g3768.
12. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370: 1781-90. http://dx.doi.org/10.1016/S0140-6736(07)60716-8.
13. Armitage J, Baigent C, Collins R. Misrepresentation of statin safety evidence. Lancet. 2014;384:1263-4. http://dx.doi.org/10.1016/S0140-6736(14)61765-7.
14. Collins R. Lack of adverse effect of statin therapy on common muscle-related adverse events. Eur J Prev Cardiol. 2015;22:1066. http://dx.doi.org/10.1177/2047487314541732
15. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90.
16. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-934. http://dx.doi.org/10.1016/j.jacc.2013.11.002.
17. National Institute for Health and Care Excellence: NICE clinical guideline no. 181. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. July 2014. http://www.nice.org.uk/guidance/cg181/resources/guidance-lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease-pdf. Accessed November 10, 2015.
18. Godlee F. Statins and The BMJ. BMJ. 2014;349:g5038.
19. Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev Clin Pharmacol. 2015;8:201-10. http://dx.doi.org/10.1586/17512433.2015.1012494
20. Doshi P, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? Trends Pharmacol Sci. 2013;34:645-7. http://dx.doi.org/10.1016/j.tips.2013.10.006
21. Strom BL, Buyse M, Hughes J, Knoppers BM. Data sharing, year 1 - access to data from industry-sponsored clinical trials. N Engl J Med. 2014;371:2052-4. http://dx.doi.org/10.1056/NEJMp1411794
22. Abbasi K. The missing data that cost $20bn. BMJ. 2014;348:g2695.
23. Protecting citizens' health: transparency of clinical trial data on medicines in the EU. Available at: http://haieurope.org/wp-content/uploads/2013/10/HAI_Protecting-citizenshealth-transparency-of-clinical-trial-data-on-medicines-in-the-EU.pdf. Accessed November 20, 2015.
24. Protecting citizens' health. Available at: http://english.prescrire.org/en/79/207/46302/2612/2506/SubReportDetails.aspx. Accessed November 20, 2015.
25. Jefferson T, Jones MA, Doshi P. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965.
26. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.
27. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med. 2013;369:475-8. http://dx.doi.org/10.1056/NEJMsr1302541
28. Jain A, Nundy S, Abbasi K. Corruption: medicine's dirty open secret. BMJ. 2014;348:g4184.
29. Eichler HG, Pétavy F, Pignatti F, Rasi G. Access to patient-level trial data - a boon to drug developers. N Engl J Med. 2013;369:1577157-9. http://dx.doi.org/10.1056/NEJMp1310771
30. Rabesandratana T. Drug watchdog ponders how to open clinical trial data vault. Science. 2013;339:1369-1370. http://dx.doi.org/10.1126/science.339.6126.1369
31. McNutt M. Reproducibility. Science. 2014;343:229. http://dx.doi.org/10.1126/science.1250475
32. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505:612-3.
33. Dwan K, Altman DG, Clarke M, Gamble C, Higgins JP, Sterne JA, et al. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med. 2014;11:e1001666. http://dx.doi.org/10.1371/journal.pmed.1001666
34. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, et al. Reanalyses of randomized clinical trial data. JAMA. 2014;312:1024-32. http://dx.doi.org/10.1001/jama.2014.9646
35. Landewé RB. How publication bias may harm treatment guidelines. Arthritis Rheumatol. 2014;66:2661-3. http://dx.doi.org/10.1002/art.38783
36. Wieseler B, Wolfram N, McGauran N, Kerekes MF, Vervölgyi V, Kohlepp P, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med. 2013;10:e1001526. http://dx.doi.org/10.1371/journal.pmed.1001526
37. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124. http://dx.doi.org/10.1371/journal.pmed.0020124
38. Ioannidis JP. How to make more published research true. PLoS Med. 2014;11:e1001747. http://dx.doi.org/10.1371/journal.pmed.1001747
39. Karha J, Topol EJ. The sad story of Vioxx, and what we should learn from it. Cleve Clin J Med. 2004;71:933-4, 936, 938-9
40. Alpert JS. The Vioxx debacle. Am J Med. 2005;118:203-4. http://dx.doi.org/10.1016/j.amjmed.2005.01.020
41. Landefeld CS, Steinman MA. The Neurontin legacy - marketing through misinformation and manipulation. N Engl J Med. 2009;360:103-6. http://dx.doi.org/10.1056/NEJMp0808659
42. Cordoba G, Schwartz L, Woloshin S, Bae H, Goetzsche PC. Definition, reporting and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920.
43. Nguyen PV. Electronic health records may threaten blinding in trials of statins. BMJ. 2014;349:g5239.
44. Blendon RJ, Benson JM, Hero JO. Public trust in physicians - U.S. medicine in international perspective. N Engl J Med. 2014;371:1570-72. http://dx.doi.org/10.1056/NEJMp1407373
45. Duncan Moore J. U.S. Physician Leaders Suffer Loss of Public Trust. Available at: http://www.medpagetoday.com/PublicHealthPolicy/GeneralProfessionalIssues/48402. Accessed November 30, 2015.
46. New Clinical Trial Regulation. Available at: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2005_28/dir_2005_28_en.pdf. Accessed November 30, 2015.
47. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products. Official Journal of the European Communities L91: 13–19. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/dir_2005_28/dir_2005_28_en.pdf. Accessed November 30, 2014.
48. Bollapragada SS, Norrie JD, Norman JE. Review of new regulations for the conduct of clinical trials of investigational medicinal products. BJOG. 2007;114:917-21. http://dx.doi.org/10.1111/j.1471-0528.2007.01415.x.
49. Hartmann M. Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials. 2012;13:53. http://dx.doi.org/10.1186/1745-6215-13-53
50. de Lorgeril M. Cholesterol and statins. Sham science and bad medicine. Vergèze, France: Thierry Souccar Publishing, 2014.
51. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. http://dx.doi.org/10.1056/NEJMoa0807646
52. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. http://dx.doi.org/10.1056/NEJMoa0706201
53. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-9.
54. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407. http://dx.doi.org/10.1056/NEJMoa0810177
55. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. http://dx.doi.org/10.1016/S0140-6736(05)67394-1
56. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024-31. http://dx.doi.org/10.1001/archinternmed.2010.182
57. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
58. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.
59. de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular disease, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170:1032-6. http://dx.doi.org/10.1001/archinternmed.2010.184
60. de Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. 2013;11:5. http://dx.doi.org/10.1186/1741-7015-11-5
61. de Lorgeril M. The JUPITER and statin controversy. American Heart Association, Los Angeles 2012. Available at: http://michel.delorgeril.info/conferences/diapositives-congres-de-l-aha-a-los-angeles. Accessed November 10, 2015.
62. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-9. http://dx.doi.org/10.1001/jama.294.17.2203
63. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303:1180-7. http://dx.doi.org/10.1001/jama.2010.310
64. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71. http://dx.doi.org/10.1016/S0140-6736(12)61190-8
65. Halimi S. Do not forget that type 2 diabetes does not only expose to cardiovascular complications. Diabetes Metab. 2014;40:167-8. http://dx.doi.org/10.1016/j.diabet.2014.03.005
66. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169:1505-22. http://dx.doi.org/10.2353/ajpath.2006.051090
67. Sieri S, Muti P, Claudia A, Berrino F, Berrino F, Pala V, Grioni S, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012;130:921-9. http://dx.doi.org/10.1002/ijc.26071
68. Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab. 2014;40:331-7. http://dx.doi.org/10.1016/j.diabet.2014.02.002
69. Carnevale V, Romagnoli E, D'Erasmo L, D'Erasmo E. Bone damage in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2014;27:1151-7. http://dx.doi.org/10.1016/j.numecd.2014.06.013
70. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al: Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170:1884-91. http://dx.doi.org/10.1001/archinternmed.2010.356
71. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-8. http://dx.doi.org/10.1016/j.jacc.2003.07.049
72. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-9. http://dx.doi.org/10.1016/j.amjcard.2004.01.039
73. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105-11. http://dx.doi.org/10.1001/jama.296.17.2105
74. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
75. Orn S, Cleland JG, Romo M, Kjekshus J, Dickstein K. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med. 2005;118:752-8. http://dx.doi.org/10.1016/j.amjmed.2005.02.010
76. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645-51. http://dx.doi.org/10.1136/bmj.39472.580984.AE
77. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al.; for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48. http://dx.doi.org/10.1056/NEJMoa043545
78. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34:1807-17. http://dx.doi.org/10.1093/eurheartj/eht065
79. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-75. http://dx.doi.org/10.7326/0003-4819-157-4-201208210-00007
80. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92. http://dx.doi.org/10.1016/S0140-6736(11)60739-3
81. Trial-Results Center. SHARP trial, description and results. Available at: http://www.trialresultscenter.org/study8081-SHARP.htm. Accessed November 15, 2015.
82. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-87. http://dx.doi.org/10.1056/NEJMoa1110874
83. Schwartz GG1, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al.; for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-8.
84. Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins? Curr Control Trials Cardiovasc Med. 2001;2:111-4.
85. National Clinical Guideline Centre (UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: National Institute for Health and Care Excellence (UK), 2014.
86. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046-56. http://dx.doi.org/10.1001/jama.295.17.2046
87. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, et al. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2014;9:CD006870.
88. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
89. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al.; for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45. http://dx.doi.org/10.1001/jama.294.19.2437
90. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670-81.
91. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658-69 Erratum in: Lancet. 2011;377:126.
92. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al.; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. Erratum in: N Engl J Med. 2006;354:778.
93. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al.; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352:1646-54. http://dx.doi.org/10.1056/NEJMoa043528
94. Neumann A, Maura G, Weill A, Ricordeau P, Alla F, Allemand H. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf. 2014;23:240-245. http://dx.doi.org/10.1002/pds.3544
95. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-61. http://dx.doi.org/10.1056/NEJMoa0900241
96. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, et al: Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 2012;9:e1001310. http://dx.doi.org/10.1371/journal.pmed.1001310
97. FDA announces safety changes in labeling for some cholesterol-lowering drugs. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. Accessed October 10, 2015.
98. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014;349:g6501.
99. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database of System Rev. 2013;12:ED000075.
100. Muscogiuri G, Sarno G, Gastaldelli A, Savastano S, Ascione A, Colao A, et al. The good and bad effects of statins on insulin sensitivity and secretion. Endocr Res. 2014;39:137-43. http://dx.doi.org/10.3109/07435800.2014.952018
101. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60:875-81. http://dx.doi.org/10.1016/j.jacc.2012.07.007
102. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42. http://dx.doi.org/10.1016/S0140-6736(09)61965-6
103. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71. http://dx.doi.org/10.1016/S0140-6736(12)61190-8
104. de Lorgeril M, Hamazaki T, Kostucki W, Okuyama H, Pavy B, McGill AT, et al. Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials. 2012;7:150-7.
105. Chang YH, Hsieh MC, Wang CY, Lin KC, Lee YJ. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients - a systematic review and meta-analysis. Rev Diabet Stud. 2013;10:157-70. http://dx.doi.org/10.1900/RDS.2013.10.157
106. Hung SH, Lin HC, Chung SD. Statin use and thyroid cancer: a population-based case-control study. Clin Endocrinol (Oxf). 2015;83:111–116. http://dx.doi.org/10.1111/cen.12570
107. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11:409. http://dx.doi.org/10.1186/1471-2407-11-409
108. de Lorgeril M, Salen P. Do statins increase and Mediterranean diet decrease the risk of breast cancer? BMC Med. 2014;12:94. http://dx.doi.org/10.1186/1741-7015-12-94
109. Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One. 2012;7:e42866. http://dx.doi.org/10.1371/journal.pone.0042866
110. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180-2. http://dx.doi.org/10.1001/archinternmed.2012.2171
111. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30:541-53. http://dx.doi.org/10.1592/phco.30.6.541
112. Ravnskov U, McCully KS, Rosch PJ. The statin - low cholesterol - cancer conundrum. QJM. 2012;105:383-8. http://dx.doi.org/10.1093/qjmed/hcr243
113. You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14:1467-76. http://dx.doi.org/10.1517/14656566.2013.803067
114. Gøtzsche PC. Muscular adverse effects are common with statins. BMJ. 2014;348:g3724.
115. Redberg RF, Katz MH. Reassessing benefits and risks of statins. N Engl J Med. 2012;367:776. http://dx.doi.org/10.1056/NEJMc1207079#SA1
116. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.
117. Sun GH: Statins: The Good, the Bad, and the Unknown. Available at: http://www.medscape.com/viewarticle/832841?src=wnl_int_edit_tp10&uac=78143HG. Accessed December 1, 2015.
118. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172:144-52. http://dx.doi.org/10.1001/archinternmed.2011.625
119. Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, et al: Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37:2225-32. http://dx.doi.org/10.2337/dc13-2215
120. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75:1118-24. http://dx.doi.org/10.1111/j.1365-2125.2012.04403.x
121. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109-1117.
122. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.; for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. http://dx.doi.org/10.1016/S0140-6736(04)16895-5
123. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478-85. http://dx.doi.org/10.2337/dc05-2415
124. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al., for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
125. März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al.; German Diabetes and Dialysis Study Investigators: Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316-25. http://dx.doi.org/10.2215/CJN.09121010
126. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care. 2011;34 (Suppl 1):S11-61.
127. American Heart Association. Cardiovascular disease and diabetes: Available: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp. Accessed November 12, 2015.
128. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. BMJ. 2012;345:e8462.
129. Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463-4. http://dx.doi.org/10.1001/jama.2013.284657